Facebook Pixel How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India | Bio Spectrum – business – Lesen Sie diese Geschichte auf Magzter.com
Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India

Bio Spectrum

|

October 2025

With India facing increasing disease burdens and deficiencies in healthcare infrastructure, AI is becoming a driving force for quicker, more intelligent therapeutic advancements. Indian startups and institutions are making significant contributions through drug repurposing, enhancing diagnostics, genomics, and clinical research.

How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India

India's healthcare system is at a pivotal moment. The numbers tell a stark story - noncommunicable diseases now cause 66 per cent of all deaths while a staggering 2.4 million hospital bed shortfall intensifies the pressure on limited infrastructure. Add to that a highly cost-sensitive market where over 50 per cent of healthcare expenses are paid out-of-pocket, and the urgency for faster, more efficient treatment pathways becomes clear.

One promising solution gaining momentum is drug repurposing - the game changing strategy of finding new therapeutic uses for existing drugs. This is accelerated by the growing adoption of artificial intelligence (AI) tools that can cut early-stage development costs by up to 50 per cent.

AI plays a crucial role in unlocking the full potential of drug repurposing by analysing vast and complex datasets such as clinical records, biomedical literature, molecular pathways, and real-world evidence to uncover hidden drug-disease relationships. Unlike traditional methods, AI enables faster hypothesis generation, predictive modeling, and risk profiling at scale. In India, where time and cost constraints are particularly acute, this ability to accelerate discovery and reduce trial-and-error makes AI not just a helpful tool, but a transformative enabler across drug development and other therapeutic areas like oncology, rare diseases, and infectious conditions.

AI in Drug Repurposing: Use Cases from India

AI-powered drug repurposing is rewriting the rulebook, cutting development time and costs by 50-60 per cent compared to building drugs from scratch. Across India, pioneering platforms are harnessing machine learning, natural language processing, and molecular modeling to breathe new life into existing compounds

Game changing AI workflows in action

WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum

Bio Spectrum

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

time to read

8 mins

March 2026

Bio Spectrum

Bio Spectrum

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

time to read

6 mins

March 2026

Bio Spectrum

Bio Spectrum

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

time to read

2 mins

March 2026

Bio Spectrum

Bio Spectrum

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

time to read

5 mins

March 2026

Listen

Translate

Share

-
+

Change font size